The Cooper Companies

COO

Medical - Instruments & Supplies · Healthcare

Also trades as: 0I3I.L

Price

$76.22

+0.06 (+0.08%)

Market Cap

$14.87B

Exchange

NASDAQ

Winston Score

Winston is serious

Mixed quality — meaningful strengths and weaknesses.

Data as of Aug 23, 2026 · filings through Apr 30, 2026

How the score breaks down

Quality

Mixed

Growth

Mixed

Cash Flow

Exceptional

Stability

Strong

Valuation

Good

Track this stock — start free trial

Winston Score History

The full picture

The Cooper Companies makes medical products sold mainly to eye doctors and women's health clinics. Its biggest division, CooperVision, makes contact lenses — including popular daily and specialty lenses — and competes with giants like Johnson & Johnson and Alcon. Its other division, CooperSurgical, makes devices and fertility-related products used by OB-GYNs and fertility clinics.

The company earns money by selling its products directly to eye care professionals and medical providers, mostly on a recurring basis since contact lens wearers need fresh lenses regularly. Cooper operates globally, with significant revenue from the Americas, Europe, and Asia-Pacific, and generated roughly $4 billion in annual revenue in recent fiscal periods. Its moat comes from strong customer relationships and a broad specialty lens portfolio, but the company carries a heavy debt load from past acquisitions — particularly CooperSurgical — which keeps its return on invested capital low and limits financial flexibility if growth slows.

Politician Trades

9 trades / 12mo

4 Congressional buys and 5 sells on COO in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+7.9% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-191.2% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$172M/ year

↑ Rising (+11% vs prior year)

4.2% of revenue

Below sector average (18%)

R&D investment increasing — building for the future

Insider Activity

0.7%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$139M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

The Cooper Companies is growing revenue at 8% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

+0.3% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 199.4M (2021) → 200.0M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

68.0%

Premium pricing power — 68.0% gross margin

Profit after running costs

Operating Margin

-2.9%

Losing money on operations — -2.9%

Return on the money invested

ROCE

4.7%

Weak — 4.7% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+6.1%

Slow sales growth (+6.1% YoY)

Profit growth

EPS YoY

-43.2%

Earnings shrinking (-43.2% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

404%

Turns 404% of profit into real cash

Spare cash per sale

FCF Margin

13.5%

Converts sales into free cash efficiently (13.5%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.30

Conservative — low debt load (0.30)

Covers its interest

Interest Cover

5.35x

Adequate interest coverage (5.3x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

64.6x

Expensive — P/E 64.6

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year

P/E vs Forward

+50.6

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (64.6 → 14.0)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial